We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Jeffrey S. Weber, MD, PhD
Ryan Sullivan, MD
Omid Hamid, MD
Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Jason J. Luke, MD, FACP
Sapna Patel, MD
Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Holding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Steven Fishbane, MD
Lucio Manenti, MD, PhD
KALMing the Itch: Improving QoL in Patients with CKD-aP
Joel Topf, MD
Kieran McCafferty, MD
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
Tara C. Mitchell, MD
Options for an Infant with Atopic Dermatitis
Peter A. Lio, MD
Mark Boguniewicz, MD
Eric Simpson, MD, MCR
Combining Biologics in a Young Patient with Atopic Dermatitis
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education